Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pramipexole

- PMLiVE

FDA approves Lilly’s GLP-1 diabetes drug Trulicity

The once-weekly treatment is set to compete with Bydureon, Tanzeum and Victoza

- PMLiVE

FDA approves AZ’s opioid-induced constipation drug Movantik

Trials showed positive reactions to the treatment

- PMLiVE

FDA panel backs Novo Nordisk’s liraglutide for obesity

Committee says diabetes drug could be used to reduce weight

- PMLiVE

Pre-chemotherapy indication for Xtandi in prostate cancer

Astellas drug set to compete with J&J’s Zytiga

- PMLiVE

Second time lucky for Takeda’s obesity drug

FDA approves Contrave three years after initial rejection

- PMLiVE

FDA panel votes against Actavis hypertension combo

Places a question mark over the combination of Bystolic and Diovan

- PMLiVE

Liraglutide seems effective in obesity, says FDA reviewer

Novo Nordisk drug is already successful diabetes treatment

- PMLiVE

Merck brings first PD-1 inhibitor to US market

FDA approves Keytruda for advanced melanoma

- PMLiVE

Drug regulators collaborate to tackle Ebola outbreak

EMA and FDA team up with global partners to accelerate access to medicines

- PMLiVE

UCB wins new epilepsy indication for Vimpat in the US

FDA approves drug as monotherapy in patients with partial-onset seizures

- PMLiVE

Takeda: No link between Actos and bladder cancer

Ten-year study backs safety of diabetes drug

- PMLiVE

Amgen claims first-to-file spot in PCSK9 inhibitor race

Evolocumab is part of new class of treatment to tackle high cholesterol

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links